Gilead Sciences' Stock Performance Amid Recent Developments in HIV and Oncology Therapies

Gilead Sciences’ Stock Performance Amid Recent Developments in HIV and Oncology Therapies

As of July 31, 2026, Gilead Sciences, Inc. (NASDAQ: GILD) reported a stock price of $130.21, reflecting a slight decrease of 0.42% from the previous close. This performance comes amid significant developments in the company’s HIV and oncology treatment portfolios.

Advancements in HIV Treatment

Gilead Sciences has been a leader in HIV therapies, and recent analyst evaluations underscore the company’s strong position in this market. On July 6, 2026, HSBC upgraded Gilead’s stock rating to “Buy,” citing an optimistic outlook for the company’s HIV treatments. The firm highlighted the potential of long-acting HIV therapies to improve patient adherence and offset declines due to the introduction of generic alternatives. HSBC also pointed to the promising growth of Gilead’s pre-exposure prophylaxis (PrEP) product, Yeztugo, as a key driver for future revenue.

Oncology Portfolio Expansion

In the oncology sector, Gilead has made strategic moves to enhance its treatment offerings. The company completed the acquisition of Arcellx, Inc., a biotechnology firm specializing in innovative immunotherapies. This acquisition grants Gilead full control over anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy targeting BCMA for the treatment of multiple myeloma. By consolidating ownership, Gilead aims to accelerate the development and commercialization of anito-cel, potentially streamlining decision-making processes and eliminating future profit-sharing obligations.

Analyst Perspectives

Analysts have responded positively to Gilead’s recent developments. Bank of America Securities raised its price target for Gilead’s stock to $162 from $154, maintaining a “Buy” rating. This adjustment follows Gilead’s strong fourth-quarter product revenues, which exceeded both Bank of America’s and consensus estimates by 4%. The firm’s analysis suggests that Gilead’s HIV franchise, bolstered by products like Biktarvy and Descovy, along with the ongoing launch of Yeztugo for HIV PrEP, positions the company for continued growth.

Conclusion

Gilead Sciences’ recent strategic initiatives in HIV and oncology treatments have garnered positive attention from analysts, reflecting confidence in the company’s direction. While the stock experienced a slight decline, the overall outlook remains optimistic, with expectations of sustained growth driven by advancements in key therapeutic areas.